Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer

Histone deacetylase inhibitors (HDACi) are small molecules targeting epigenetic enzymes approved for hematologic neoplasms, which have also demonstrated clinical activities in solid tumors. In our present study, we screened our internal compound library and discovered a novel HDACi, WW437, with pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Tao, Li, Jingjie, Ma, Xiaojun, Yang, Yang, Sun, Wei, Jin, Wangrui, Wang, Lei, He, Yuan, Yang, Feifei, Yi, Zhengfang, Hua, Yingqi, Liu, Mingyao, Chen, Yihua, Cai, Zhengdong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013969/
https://www.ncbi.nlm.nih.gov/pubmed/29759486
http://dx.doi.org/10.1016/j.ebiom.2018.05.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013969/
https://www.ncbi.nlm.nih.gov/pubmed/29759486
http://dx.doi.org/10.1016/j.ebiom.2018.05.003

Ejemplares similares